Mereo Biopharma Group plc
SEC CIK 1719714 · MREO · last insider filing 2026-02-27
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Wyzga Michael S | Director | filed 2024 - 2026 |
| Pakianathan Deepika | Director | filed 2024 - 2026 |
| Yoskowitz Marc J | Director | filed 2024 - 2026 |
| Jenkins Annalisa | Director | filed 2024 - 2026 |
| Jacquet Pierre | Director | filed 2024 - 2026 |
| Bender Jeremy | Director | filed 2024 - 2026 |
| Shames Daniel | Director | filed 2024 - 2026 |
| Ekblom Anders | Director | filed 2024 - 2026 |
| Scots-Knight Denise | Director · Chief Executive Officer | filed 2024 - 2026 |
| Roberts Justin Hunter | Director | filed 2024 - 2024 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Lewicki John A. | Chief Scientific Officer | filed 2024 - 2026 |
| Sermon Charles | General Counsel | filed 2024 - 2026 |
| Fox Christine Ann | Chief Financial Officer | filed 2024 - 2026 |
| Hughes-Wilson Alexandra | See Remarks | filed 2024 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.